uploads/2018/01/RDUS-Analysts-Reco-1.png

Analysts’ Ratings for Radius Health and Its Peers in January

By

Updated

Company overview

Radius Health (RDUS) is a biopharmaceutical company that has recently turned into a commercial stage healthcare company. The company is focused on developing and commercializing therapies in the areas of osteoporosis, oncology, and endocrine diseases.

In April 2017, Radius received FDA approval for its first commercial product, Tymlos. Tymlos was approved for the treatment of postmenopausal women with osteoporosis at a high risk for fracture.

Analysts’ ratings

Of the seven analysts covering Radius Health in January 2018, three have given the stock “buy” or higher ratings, while four have given it “hold” ratings. The mean rating for the stock is 2.43, and it has a target price of $47.5.

Radius Health makes up ~0.12% of the iShares Russell 2000 Growth ETF’s (IWO) total portfolio holdings.

Peers’ ratings

Of the four analysts covering Novartis (NVS) in January 2018, two analysts have given the stock “buy” or higher ratings. The mean rating for the stock is 2.5, and its target price is $93.

Of the 24 analysts covering Pfizer (PFE) in January 2018, 13 analysts have given the stock “buy” or higher ratings, while nine analysts have given it “hold” ratings. The mean rating for the stock is 2.54, and it has a target price of $38.57.

Of the nine analysts covering Array Biopharma (ARRY) in January 2018, eight analysts have given the stock “buy” or higher ratings, while one analyst has given it a “hold” rating. The mean rating for the stock is 1.78, and its target price is $16.22.

In the next part of the series, we’ll take a look at the promising candidates in Radius Health’s drug pipeline.

 

More From Market Realist